Alnylam receives $20 million milestone from Takeda
This article was originally published in Scrip
Alnylam Pharmaceuticals has received a milestone payment of $20 million from Takedaas part of the companies' May alliance for RNA interference therapeutics. The sum was for the transfer of selected technology, materials and know-how under the potential $1 billion-plus global tie-up, which could see the US firm receive a further $30 million in near-term milestones. The collaboration is focusing on oncology and metabolic disease initially and also involves the cross licensing of delivery technologies and a joint discovery programme. Alnylam has an option to co-develop and co-commercialise in the US any Takeda RNAi therapeutics emerging from the agreement (Scrip Online, May27th, 2008).
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context